On the research front last week, China-based biotech Remegen released positive Phase III results for its telitacicept in ...

The US subsidiary of Chinese biotech VelaVigo Cayman Limited has announced its second out-licensing agreement of a ...

The National Board of Health and Welfare will pay 80 million kronor ($8.3 million) to the national initiative Genomic ...

London, UK-based Alis Biosciences, an investment fund focused on returning capital to investors that is currently trapped in ...

The DESTINY-Breast09 Phase III trial of AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab ...